Clinical effects of the levonorgestrel-releasing intrauterine device in patients with adenomyosis

Levonorgestrel intrauterine releasing system: long term health impact

“…The other studies conducted on the subject also show that LNG IUS decreases the menstrual flow, dysmenorrhoea score, mean uterine volume and uterine artery blood flow. 10,11 However, as with uterine size, the pain scores and blood flow increased again after 36 months, though they were still significantly less than the initial values. Though the exact cause for this phenomenon is unknown, it is hypothesized that it could be attributed to the decreased amount of hormone released by the LNG-IUS daily overtime.…”

“…Though the exact cause for this phenomenon is unknown, it is hypothesized that it could be attributed to the decreased amount of hormone released by the LNG-IUS daily overtime. 11 Regardless, the LNG-IUS does appear to be an effective treatment for adenomyosis with improvement in pain and bleeding scores over two years. Further studies will need to address whether replacing the LNG-IUS after 2-3 years will keep the pain and bleeding scores from increasing again over time.…”

Levonorgestrel containing intrauterine device (Mirena®) in the treatment of dyfunctional uterine bleeding; patients’ view and our experience

“…In the literature, expulsion rate of Mirena® is found to be 7.5% 10 , 8.5% 11 and 16% 12 , and 37.5% 13 . Higher expulsion rates seem to be associated with large uterine volume 6 .…”

Single‐ and Multiple‐Day Dosing Studies to Investigate High‐Dose Pharmacokinetics of Epelsiban and Its Metabolite, GSK2395448, in Healthy Female Volunteers

“…10 Dosing in each cohort occurred sequentially. Dose escalation proceeded once preliminary safety/tolerability (days [1][2][3][4][5][6][7][8][9][10][11][12][13][14] and PK data (days 1 and 7) had been reviewed for all subjects at the previous dose. Blood samples for safety and PK analysis were collected on days 1, 7, and 14 of the 14-day in-house treatment period.…”

“…In the United States, hysterectomy remains the treatment of choice when future fertility is not an issue, if extensive disease precludes a minimally invasive procedure or if other less invasive modalities fail. 8,9 Epelsiban (GSK557296) is a potent and selective oxytocin receptor (OXTR) antagonist previously in development for the treatment of adenomyosis. In vitro receptor binding and functional assays have demonstrated epelsiban potency in the nanomolar, or lower, affinity for rat, baboon, and human (K i of 0.09 to 11 nM) oxytocin receptors, which is also highly selective (>27 000-fold) for the human oxytocin receptor versus human V1a, V1b, and V2 vasopressin receptors (unpublished results).…”